USFDA EIR for OmniChem Vizag facility

October 06, 2017 10:37 pm | Updated October 28, 2017 06:21 pm IST - hyderabad

USFDA issues EIR for OmniChem facility

Shares of pharma firm Granules India Ltd. on Friday gained 6.37% to close at ₹121.85 on the back of the U.S. Food and Drug Administration issuing the Establishment Inspection Report (EIR) for the OmniChem facility in Visakhapatnam. The facility, which manufactures API intermediates, is a 50:50 joint venture of Granules India and Ajinomoto OmniChem N.V. The USFDA has issued EIR for the facility, Granules said in a regulatory filing to the stock exchange.

The regulator had inspected the facility in December 2016 and made seven observations, the release said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.